Geode Capital Management LLC Has $8.41 Million Holdings in TherapeuticsMD Inc (TXMD)

Share on StockTwits

Geode Capital Management LLC raised its position in shares of TherapeuticsMD Inc (NASDAQ:TXMD) by 9.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,206,185 shares of the company’s stock after acquiring an additional 183,048 shares during the period. Geode Capital Management LLC’s holdings in TherapeuticsMD were worth $8,405,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc increased its position in TherapeuticsMD by 9.8% during the third quarter. Vanguard Group Inc now owns 12,894,027 shares of the company’s stock valued at $84,585,000 after acquiring an additional 1,153,716 shares during the last quarter. Frontier Capital Management Co. LLC purchased a new stake in shares of TherapeuticsMD during the fourth quarter valued at $5,700,000. BlackRock Inc. boosted its stake in shares of TherapeuticsMD by 10.6% during the third quarter. BlackRock Inc. now owns 16,070,569 shares of the company’s stock valued at $105,421,000 after purchasing an additional 1,537,045 shares during the period. Teachers Advisors LLC boosted its stake in shares of TherapeuticsMD by 13.3% during the third quarter. Teachers Advisors LLC now owns 353,895 shares of the company’s stock valued at $2,322,000 after purchasing an additional 41,607 shares during the period. Finally, Dfpg Investments Inc. purchased a new stake in shares of TherapeuticsMD during the fourth quarter valued at $38,000. Institutional investors and hedge funds own 77.32% of the company’s stock.

In related news, Director Jules A. Musing sold 17,400 shares of the company’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $5.80, for a total value of $100,920.00. Following the completion of the sale, the director now directly owns 5,000 shares of the company’s stock, valued at $29,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 22.85% of the stock is owned by corporate insiders.

A number of brokerages have recently issued reports on TXMD. BidaskClub lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Wednesday, April 3rd. ValuEngine lowered shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Sunday, February 10th. reissued a “buy” rating and set a $14.00 target price on shares of TherapeuticsMD in a research note on Tuesday, February 12th. Cantor Fitzgerald reissued a “buy” rating and set a $27.00 target price on shares of TherapeuticsMD in a research note on Monday, January 21st. Finally, Zacks Investment Research lowered shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $14.45.

Shares of TXMD opened at $4.47 on Tuesday. The firm has a market cap of $1.10 billion, a PE ratio of -7.58 and a beta of 2.06. TherapeuticsMD Inc has a 12-month low of $3.51 and a 12-month high of $7.66. The company has a quick ratio of 4.47, a current ratio of 4.55 and a debt-to-equity ratio of 0.75.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Thursday, February 21st. The company reported ($0.17) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.17). TherapeuticsMD had a negative net margin of 823.71% and a negative return on equity of 127.34%. The company had revenue of $5.09 million during the quarter, compared to analyst estimates of $5.03 million. Analysts predict that TherapeuticsMD Inc will post -0.65 EPS for the current year.

WARNING: “Geode Capital Management LLC Has $8.41 Million Holdings in TherapeuticsMD Inc (TXMD)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4296188/geode-capital-management-llc-has-8-41-million-holdings-in-therapeuticsmd-inc-txmd.html.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Recommended Story: What is Blockchain?

Want to see what other hedge funds are holding TXMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TherapeuticsMD Inc (NASDAQ:TXMD).

Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Keith Piggott Sells 175,000 Shares of Core Gold Inc  Stock
Keith Piggott Sells 175,000 Shares of Core Gold Inc Stock
Medical Properties Trust, Inc.  Expected to Announce Quarterly Sales of $185.35 Million
Medical Properties Trust, Inc. Expected to Announce Quarterly Sales of $185.35 Million
The Sage Group plc  Given Average Rating of “Hold” by Analysts
The Sage Group plc Given Average Rating of “Hold” by Analysts
BioMarin Pharmaceutical Inc.  Receives $116.25 Average Price Target from Brokerages
BioMarin Pharmaceutical Inc. Receives $116.25 Average Price Target from Brokerages
Linkey Price Reaches $0.60 on Exchanges
Linkey Price Reaches $0.60 on Exchanges
Aeon Market Capitalization Achieves $6.00 Million
Aeon Market Capitalization Achieves $6.00 Million


© 2006-2019 Ticker Report